These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24930060)

  • 21. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 22. [Which anti-tumour benefits to be expected from metformin?].
    Beck E; Scheen AJ
    Ann Endocrinol (Paris); 2013 May; 74(2):137-47. PubMed ID: 23566618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
    Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
    Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
    Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
    Diabetologia; 2009 Sep; 52(9):1971-3. PubMed ID: 19609501
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
    J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.
    Soranna D; Scotti L; Zambon A; Bosetti C; Grassi G; Catapano A; La Vecchia C; Mancia G; Corrao G
    Oncologist; 2012; 17(6):813-22. PubMed ID: 22643536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study.
    Buchs AE; Silverman BG
    Metabolism; 2011 Oct; 60(10):1379-85. PubMed ID: 21696791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.
    Farmer RE; Ford D; Forbes HJ; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
    Int J Epidemiol; 2017 Apr; 46(2):728-744. PubMed ID: 28031313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes.
    Erkinantti S; Marttila M; Sund R; Arffman M; Urpilainen E; Puistola U; Hautakoski A; Karihtala P; Läärä E; Jukkola A
    Clin Colorectal Cancer; 2021 Jun; 20(2):e113-e119. PubMed ID: 33279415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity of Metformin and Hypoglycemic Therapies.
    Akhter MS; Uppal P
    Adv Chronic Kidney Dis; 2020 Jan; 27(1):18-30. PubMed ID: 32146997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.
    Scott LJ
    Drugs; 2017 Aug; 77(12):1353-1362. PubMed ID: 28667587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes and cancer: a consensus report.
    Giovannucci E; Harlan DM; Archer MC; Bergenstal RM; Gapstur SM; Habel LA; Pollak M; Regensteiner JG; Yee D
    CA Cancer J Clin; 2010; 60(4):207-21. PubMed ID: 20554718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
    Losada E; Soldevila B; Ali MS; Martínez-Laguna D; Nogués X; Puig-Domingo M; Díez-Pérez A; Mauricio D; Prieto-Alhambra D
    Osteoporos Int; 2018 Sep; 29(9):2079-2086. PubMed ID: 29860664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
    Donadon V; Balbi M; Zanette G
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):465-7. PubMed ID: 19817667
    [No Abstract]   [Full Text] [Related]  

  • 36. Diabetes and pancreatic cancer.
    Muniraj T; Chari ST
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):331-45. PubMed ID: 23207610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cancer more common in diabetes. Maybe the treatment itself also plays a role].
    Nilsson PM; Eliasson B
    Lakartidningen; 2010 Jan 27-Feb 2; 107(4):170-1. PubMed ID: 20333969
    [No Abstract]   [Full Text] [Related]  

  • 39. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.